Competing interests
TG
Financial arrangements of the authors with companies whose products may be related to the present manuscript are listed, as declared by the authors. XB: Received grant/research support from, consultant for, and is a member of speaker bureaus for AbbVie, Bristol Myers Squibb, Celgene, Chugai, Eli Lilly, Galapagos, Gilead, MSD, Novartis, Pfizer, and UCB. RR: Consultant for AbbVie, Janssen, Novartis, and Pfizer; and is a member of speaker bureaus for AbbVie, Janssen, Novartis, and Pfizer. AÖ: Consultant for AbbVie, Bristol Myers Squibb, Eli Lilly, Gilead, MSD, Novartis, Pfizer, and Roche; member of speaker bureaus for AbbVie, Bristol-Myers Squibb, Eli Lilly, Gilead, MSD, Novartis, Pfizer, and Roche. FC: Received grant/research support from AbbVie, Celgene, Pfizer, Roche, and UCB; consultant for AbbVie, Bristol-Myers Squibb, Celgene, MSD, Novartis, Pfizer, Janssen, Sanofi, Sandoz, Galapagos, Sobi, and UCB; member of speaker bureaus for AbbVie, Bristol-Myers Squibb, Celgene, Novartis, Pfizer, and UCB. LCC: Received grant/research support from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer and UCB; consultant for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Moonlake, Novartis, Pfizer and UCB; speaker for AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Medac, Novartis, Pfizer and UCB. SR: Received grant/research support from AbbVie, Boehringer Ingelheim, Eli Lilly, MSD, Novartis, Pfizer, and UCB; consultant for AbbVie, Boehringer Ingelheim, Eli Lilly, MSD, Novartis, and Pfizer. JAW: Grants or consulting with AbbVie, Amgen, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB. KD: Employee of AbbVie and may hold stock or options. TG: Employee of AbbVie and may hold stock or options. KK: Employee of AbbVie and may hold stock or options. I-HS: Employee of AbbVie and may hold stock or options. FG: Employee of AbbVie and may hold stock or options. AD: Received research grants, consultancy fees, speaker fees, and other support (medical writing support) from Eli Lilly, Novartis, Pfizer and UCB; research grants, consultancy fees, and other support (medical writing support) from AbbVie, Bristol Myers Squibb, Eli Lilly, and UCB; research grants and consultancy fees from GlaxoSmithKline; consultancy fees and other support (medical writing support) from Janssen; consultancy fees from Bristol Myers Squibb and Celgene; and other support (medical writing support) from Amgen.